Kimberly-Clark (KMB) beat expectations in FY2026 on revenue of $64.4B versus the $62.6B estimate (+12.1% YoY) and EPS of $0.70. Below is the full Kimberly-Clark earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$64.4B (vs $62.6B est · +2.9% surprise · +12.1% YoY)
EPS
$0.70 (vs $0.67 est · +4.5% surprise · +17.5% YoY)
Share price
$162.35 (-2.4%)
Market cap
$870.0B
What you'll find
Next Kimberly-Clark (KMB) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Kimberly-Clark reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Kimberly-Clark (KMB)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Kimberly-Clark's next earnings date?
Kimberly-Clark's (KMB) next scheduled earnings date is Feb 6, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Kimberly-Clark (KMB) beat or miss earnings?
In FY2026, Kimberly-Clark (KMB) posted beat results — revenue of $64.4B versus the $62.6B estimate (+2.9% surprise) and EPS of $0.70 versus $0.67 expected (+4.5% surprise). Magnisto decodes every Kimberly-Clark (KMB) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Kimberly-Clark (KMB) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Kimberly-Clark (KMB), anchored to the current $162.35 share price, so you can weigh the bull, base and bear cases for Kimberly-Clark side by side.
Is Kimberly-Clark (KMB) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Kimberly-Clark fits your own thesis and risk profile. This is research, not investment advice.